Is Apimeds Pharmaceuticals US Inc halal to invest in?

According to Musaffa's Shariah screening methodology, Apimeds Pharmaceuticals US Inc (APUS) is currently classified as NOT HALAL as of May 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Apimeds Pharmaceuticals US Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Apimeds Pharmaceuticals US Inc using these criteria to determine its compliance status.

Can Muslims buy shares of Apimeds Pharmaceuticals US Inc?

Muslim investors may consider investing in Apimeds Pharmaceuticals US Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Apimeds Pharmaceuticals US Inc classified as NOT HALAL?

Musaffa determines the Shariah status of Apimeds Pharmaceuticals US Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Apimeds Pharmaceuticals US Inc updated?

The Shariah compliance status of Apimeds Pharmaceuticals US Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Apimeds Pharmaceuticals US Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Apimeds Pharmaceuticals US Inc?

You can check the latest Shariah compliance status of Apimeds Pharmaceuticals US Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

APUS Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: May 11, 2026

Report Source: 2025 Annual Report

Apimeds Pharmaceuticals US Inc. Stock Analysis APUS

United States Health Care Nano Cap Report: 2025 Annual

Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company that engages in the development of Apitox, an intradermally administered bee venom-based toxin. The company is headquartered in Matawan, New Jersey and currently employs 2 full-time employees. The company went IPO on 2025-05-09. The firm is engaged in developing Apitox, an intradermally administered bee venom-based toxin. The company is focused on developing Apitox in the treatment of inflammatory conditions in the United States, specifically osteoarthritis and multiple sclerosis. Its subsidiary, MindWave Innovations Inc, is a provider of institutional digital asset treasury (DAT) solutions.

Key Statistics of Apimeds Pharmaceuticals US Inc (APUS)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$1.34$1.52

Today's Open

$1.34

Volume

69.82K

P/E Ratio (TTM)

52 Week Range

$1.24$40.31

Market Cap

37.73M

Avg. Volume

798.53K

Dividend Yield

Financial Metrics & Statements of Apimeds Pharmaceuticals US Inc (APUS)

FAQ's for Apimeds Pharmaceuticals US Inc (APUS)

According to Musaffa’s Shariah screening methodology, Apimeds Pharmaceuticals US Inc (APUS) is currently classified as NOT HALAL as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.